Strategic Consulting and Tactical Execution for the Health Care Industry
Early-stage scientific founders and scientists are in need of more customized and strategic support to save cost, time, and resources. These pioneers are poised to make the world a better place and we are here to help provide that precision guidance. HALO Point Solutions was established to provide precision guidance to early-stage healthcare companies. Offering services in R&D, analytical testing, product development, business development, fundraising, and marketing, HALO Point is there to focus healthcare companies on achieving regulatory clearance and market success.
HALO Point Solutions is committed to aiding researchers to provide precision guidance from early development to launch more effectively. Offering services in R&D, analytical testing, product development, business development, fundraising, and marketing, HALO Point is there to focus healthcare companies on achieving regulatory clearance and market success.
“An entrepreneur is someone who will jump off a cliff and assemble an airplane on the way down.”
– Reid Hoffman
H.A.L.O. (High Altitude Low Opening) is a tactical skill performed by the special force elites to go from 25,000 ft to a precise landing zone. We recognize that this is like what pioneers at early-stage startups go through to develop their product for regulatory approval and launch. We established HALO Point Solutions to provide precision guidance to these pioneers who dare to jump to make this world a better place.
We are the industry heads and produce the most reliable and trendy solution you are looking for.
Services for early-stage health care companies or products
- Natural extension of your team: availability for duration of projects
- Reduce waste resource and time by focusing on efficient methods and cost savings
- Risk management and executing right workstreams
- Core cross-functional team to allow better decisions
- One-stop shop- Lab, platform, and tools
- US product launch plans
- Preclinical IND enabling studies
- Drug and lead compound development
- Business operation and program management
- Own R&D process
- US Strategy, marketing, pre-launch
- Companion diagnostics
- KOL development and publication strategies
- Commercial strategy and launch into US market
Analytical and Analysis
- Pre-formulation Studies
- Formulation development
- Bioanalytical/Analytical Development
- Dissolution Testing
- Stability/Shelf-life Studies
- By Specific Analyte
- Mechanism of Action
- In vivo studies
- Strategic direction of infectious disease tests
- Launched and grew infectious disease testing services and platforms
- Revitalizing a novel compound for pharma company
- Companion Diagnostics
- Market access and launch of sensor medical devices
- Academic early concept validation
- Compound analysis for pharmas and CBD companies
Early stage companies can benefit from a well-structured path that minimizes risk and prioritizes drug to market. An early focus on validating technology and balancing in-house resources with CRO’s are key to their success.
Medical device companies are subject to an ever expanding set of regulations and require a seasoned but focused strategy to avoid the common pitfalls that slow these companies down.
The COVID-19 pandemic has provided a spotlight on diagnostic supply chain and the importance of rapid wide spread testing in managing outbreaks. This industry is poised for a revolution in healthcare.
Ricky Kim is a mission-driven problem solver with a perfect blend of strategic thinking and execution, indefatigable in finding a solution to healthcare problems. He has over 18 years of combined experience in research, product development, strategic marketing, product launches focusing on driving organic growth. He has helped both start-ups and fortune 500 companies achieve success and is now poised to use all of the trades to help early-stage companies. He graduated with a BS in Biology from Brandeis University and an MBA from Boston University. He enjoys training for Ironman or cycling races.
Herman Lelie, PhD. is a leading R&D consultant in the healthcare industry focused on delivering clarity and direction to a strong scientific-based process. Blending a diverse background that includes pharmaceutical R&D, medical device engineering, marketing, regulatory, quality, clinical and corporate strategy, he excels at working cross functionally by managing expectations and fostering positive communication. Having successfully led and obtained over $3M in grants from the NIH, NASA, DOD, and CDC, the word “no” does not exist in his vocabulary. He graduated with a BS in Chemistry from MIT and Ph.D. in Molecular Biology and Biochemistry from UCLA. Dr. Lelie likes to spend his free time learning about new things such as programming, artificial intelligence, bioinformatics, and library and information science.